#investor-pressure

[ follow ]
fromFortune
2 weeks ago

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

Kenvue faces challenges in growth and profitability, leading to CEO resignation and strategic review after a 4% expected drop in net sales.
[ Load more ]